Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture

Epilepsy Research

Volumn 88, Issue 1, 2010, Pages 46-54

  Zona, Cristina ^a,b   Pieri, Massimo ^a,b   Carunchio, Irene ^a,b   Curcio, Livia ^a,b   Klitgaard, Henrik ^c   Margineanu, Doru Georg ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UCB PHARMA   (Belgium)

Author keywords

Brivaracetam (ucb 34714); Fast inactivation kinetics; Levetiracetam (Keppra ); Steady state activation; Voltage activated Na+ current

Indexed keywords

ANTICONVULSIVE AGENT; BRIVARACETAM; MEMBRANE PROTEIN; SYNAPTIC VESICLE PROTEIN; UNCLASSIFIED DRUG; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL CELL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING SITE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; HYPERPOLARIZATION; IC 50; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM CURRENT; STEADY STATE; SYNAPSE VESICLE; VOLTAGE ACTIVATED SODIUM CURRENT; WHOLE CELL;

ANIMALS; ANTICONVULSANTS; BIOPHYSICS; CELLS, CULTURED; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; EMBRYO, MAMMALIAN; ION CHANNEL GATING; MEMBRANE POTENTIALS; NEURONS; PATCH-CLAMP TECHNIQUES; PYRROLIDINONES; RATS; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS; TETRODOTOXIN;

EID: 72249118204     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.09.024     Document Type: Article

References (34)

1. Bean B.P., Cohen C.J., and Tsien R.W. Lidocaine block of cardiac sodium channels. J. Gen. Physiol. 81 (1983) 613-642
2. Catterall W.A. Molecular properties of brain sodium channels: an important target for anticonvulsant drugs. Adv. Neurol. 79 (1999) 441-456
3. Contreras D. Electrophysiological classes of neocortical neurons. Neural Netw. 17 (2004) 633-646
4. Hamill O.P., Marty A., Neher E., Sakmann B., and Sigworth F.J. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflügers Arch. 391 (1981) 85-100
5. Harkin L.A., McMahon J.M., Iona X., Dibbens L., Pelekanos J.T., Zuberi S.M., Sadleir L.G., Andermann E., Gill D., Farrell K., Connolly M., Stanley T., Harbord M., Andermann F., Wang J., Batish S.D., Jones J.G., Seltzer W.K., Gardner A., Sutherland G., Berkovic S.F., Mulley J.C., and Scheffer I.E. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130 (2007) 843-852
6. Hondeghem L.M., and Katzung B.G. Time and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim. Biophys. Acta 472 (1977) 373-398
7. Kaminski R., Matagne A., Leclercq K., Gillard M., Michel Ph., Kenda B., Talaga P., and Klitgaard H. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 54 (2008) 715-720
8. Kaminski R., Gillard M., Leclercq K., Hanon E., Lorent G., Dassesse D., Matagne A., and Klitgaard H. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 50 7 (2009) 1729-1740
9. Kenda B.M., Matagne A.C., Talaga P.E., Pasau P.M., Differding E., Lallemand B.I., Frycia A.M., Moureau F.G., Klitgaard H.V., Gillard M.R., Fuks B., and Michel P. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J. Med. Chem. 47 (2004) 530-549
10. Klitgaard H., Matagne A., Gobert J., and Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol. 353 (1998) 191-206
11. Köhling R. Voltage-gated sodium channels in epilepsy. Epilepsia 43 (2002) 1278-1295
12. Kriegstein A.R., and Dichter M.A. Morphological classification of rat cortical neurons in cell culture. J. Neurosci. 3 (1983) 1634-1647
13. + channels must deactivate to recover from inactivation. Neuron 12 (1994) 819-829
14. + channels in rat hippocampal neurons. Br. J. Pharmacol. 121 (1997) 1231-1238
15. Large C., Kalinichev M., Lucas A., Carignani C., Bradford A., Garbati N., Sartori I., Austin N., Ruffo A., and Jones D. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Res. 85 (2009) 96-106
16. Lenkowski P.W., Batts T.W., Smith M.D., Ko S.-H., Jones P.J., Taylor C.H., McCusker A.K., Davis G.C., Hartmann H.A., White H.S., Brown M.L., and Patel M.K. A pharmacophore derived phenytoin analogue with increased affinity for slow inactivated sodium channels exhibits a desired anticonvulsant profile. Neuropharmacol. 52 (2007) 1044-1054
17. Liu G., Yarov-Yarovoy V., Nobbs M., Clare J.J., Scheuer T., and Catterall W.A. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels. Neuropharmacology 44 (2003) 413-422
18. Lossin C., Wang D.W., Rhodes T.H., Vanoye C.G., and George Jr. A.L. Molecular basis of an inherited epilepsy. Neuron 34 (2002) 877-884
19. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., and Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 9861-9866
20. Matagne A., Margineanu D.G., Kenda B., Michel P., and Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br. J. Pharmacol. 154 (2008) 1662-1671
21. Mulley J.C., Scheffer I.E., Petrou S., Dibbens L.M., Berkovic S.F., and Harkin L.A. SCN1A mutations and epilepsy. Hum. Mutat. 25 (2005) 535-542
22. Ragsdale D.S., and Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res. Brain Res. Rev. 26 (1998) 16-28
23. Rhodes T.H., Lossin C., Vanoye C.G., Wang D.W., and George Jr. A.L. Noninactivating voltage-gated sodium channels in severe myoclonic epilepsy of infancy. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11147-11152
24. Rogawski M.A., and Löscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci. 5 (2004) 553-564
25. Sargentini-Maier M.L., Rolan P., Connell J., Tytgat D., Jacobs T., Pigeolet E., Riethuisen J.-M., and Stockis A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br. J. Clin. Pharmacol. 63 (2007) 680-688
26. Spampanato J., Escayg A., Meisler M.H., and Goldin A.L. Functional effects of two voltage-gated sodium channel mutations that cause generalized epilepsy with febrile seizures plus type 2. J. Neurosci. 21 (2001) 7481-7490
27. Spampanato J., Escayg A., Meisler M.H., and Goldin A.L. Generalized epilepsy with febrile seizures plus type 2 mutation W1204R alters voltage-dependent gating of Na(v)1.1 sodium channels. Neuroscience 116 (2003) 37-48
28. Sun G.C., Werkman T.R., Battefeld A., Clare J.J., and Wadman W.J. Carbamazepine and topiramate modulation of transient and persistent sodium currents studied in HEK293 cells expressing the Na(v)1.3 alpha-subunit. Epilepsia 48 (2007) 774-782
29. + current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 288 (1999) 960-968
30. Torkkeli P.H., and French A.S. Simulation of different firing patterns in paired spider mechanoreceptor neurons: the role of Na(+) channel inactivation. J. Neurophysiol. 87 (2002) 1363-1368
31. von Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics 4 (2007) 84-87
32. Zona C., and Avoli M. Lamotrigine reduces voltage-gated sodium currents in rat central neurons in culture. Epilepsia 38 (1997) 522-525
33. Zona C., Ciotti M.T., and Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci. Lett. 231 (1997) 123-126
34. 2+ currents. Seizure 10 (2001) 279-286